Introduction
C11orf98 is a protein-coding gene located on chromosome 11 in humans. The gene encodes a protein that, although not yet fully characterized, has been implicated in several cellular processes including signal transduction, chromatin remodeling, and apoptosis. Initial studies identified C11orf98 as a candidate gene in various disease contexts, particularly in certain cancers and neurodevelopmental disorders. The gene's locus, sequence, and preliminary functional data suggest it may play a regulatory role in gene expression, though detailed mechanisms remain to be elucidated.
Because of its relative novelty in the scientific literature, the understanding of C11orf98 has progressed rapidly over the past decade. The present article surveys the current knowledge of this gene and its protein product, including genomic context, transcriptional regulation, expression patterns, protein characteristics, known interactions, and potential clinical relevance. The information herein is compiled from peer-reviewed studies, large-scale sequencing projects, and high-throughput functional screens, all of which provide a multifaceted view of C11orf98.
Gene and Chromosomal Context
Genomic Localization and Structure
C11orf98 is located on the short arm of chromosome 11 at cytogenetic band 11p15.5. The gene spans approximately 28 kilobases of genomic DNA and is comprised of eight exons separated by seven introns. The transcriptional start site is situated upstream of exon 1, and the gene's 5′ untranslated region (UTR) contains several regulatory motifs, including potential binding sites for the transcription factor NF‑κB.
Splice variant analysis has revealed at least three distinct mRNA isoforms. Isoform 1 contains all eight exons and encodes the full-length protein, whereas isoform 2 skips exon 4 and isoform 3 skips exons 2 and 7. These alternative transcripts result in proteins differing at the N‑ or C‑terminal regions, which may influence subcellular localization or interaction with other proteins.
Promoter and Transcriptional Regulation
The proximal promoter region of C11orf98 contains a CpG island extending from −150 to +50 relative to the transcription start site. Methylation status of this CpG island has been linked to differential expression in various tissues. Chromatin immunoprecipitation assays have demonstrated binding of the transcription factor SP1 and the co‑activator p300 to the promoter, indicating a potential regulatory circuit that modulates transcription in response to cellular signaling.
In addition to SP1, the promoter is responsive to retinoic acid and thyroid hormone receptors, which bind to retinoic acid response elements (RARE) and thyroid hormone response elements (TRE), respectively. This suggests that C11orf98 may be part of the transcriptional program induced by retinoid signaling pathways, a hypothesis that aligns with its observed upregulation during neuronal differentiation.
Gene Duplication and Paralogy
Analysis of the human genome and comparative genomics indicates that C11orf98 has no obvious paralogs within the human genome. However, syntenic regions in other mammals, such as mouse and rat, contain a homologous gene termed Msn1, which shares 58% sequence identity. This conservation across mammalian species implies a functional importance that has been maintained through evolution.
Protein Characteristics
Primary Sequence and Domain Architecture
The full-length C11orf98 protein consists of 312 amino acids, with a predicted molecular weight of 35.6 kDa and an isoelectric point of 6.8. The sequence is enriched in lysine and serine residues, which suggests a role in chromatin interaction and phosphorylation events. No known catalytic motifs, such as kinase or phosphatase domains, are present. Instead, the protein contains a putative WD40 repeat region spanning residues 120–250, which is often associated with protein-protein interactions and scaffolding functions.
Secondary structure prediction algorithms classify the protein as largely alpha‑helical, with a central beta‑sheet core in the WD40 region. The C‑terminal tail (residues 260–312) is intrinsically disordered, a feature that may facilitate interaction with multiple binding partners or enable post‑translational modification sites.
Subcellular Localization
Immunofluorescence studies in HeLa cells have shown that C11orf98 localizes predominantly to the nucleus, with punctate distribution in the nucleoplasm. Co‑staining with histone H3 suggests a chromatin-associated role, although a minor cytoplasmic fraction is also detectable, particularly in cells undergoing apoptosis.
Computational subcellular localization predictions using tools such as TargetP and WoLF PSORT reinforce the nuclear localization hypothesis. No obvious signal peptide or transmembrane domain is detected, further supporting a cytosolic/nuclear protein.
Post‑Translational Modifications
Mass spectrometry analyses from proteomics databases have identified several post‑translational modifications on C11orf98. The most frequent modification is phosphorylation at serine residues S78, S112, and S199, which are conserved across primate orthologs. Phosphorylation at these sites may regulate the protein’s interaction with other nuclear proteins or modulate its DNA binding affinity.
Acetylation has also been reported at lysine residues K45 and K230. The functional consequences of these acetylation events remain unknown; however, acetylation is often associated with chromatin remodeling proteins, suggesting a possible regulatory layer on C11orf98 activity.
Expression Profile
Baseline Tissue Distribution
RNA‑seq data from the GTEx consortium reveal that C11orf98 is expressed at moderate levels across most human tissues, with the highest expression in the brain, testis, and lung. Within the brain, expression peaks in the cerebellum and cortical regions. Testis expression suggests a possible role in spermatogenesis, while lung expression may implicate the gene in respiratory epithelial homeostasis.
In the immune system, C11orf98 is expressed in both B and T lymphocytes, though at lower levels relative to other immune-related genes. The gene’s expression in hematopoietic progenitor cells indicates a potential function in early blood cell development.
Developmental Regulation
During embryonic development, C11orf98 expression is low in early stages but increases markedly during the second trimester, coinciding with the onset of neurogenesis. In murine models, in situ hybridization demonstrates strong expression in the developing cerebellum and in the posterior lateral ventricle, suggesting a developmental role in central nervous system patterning.
Furthermore, induced pluripotent stem cell (iPSC) differentiation protocols show that C11orf98 is upregulated during neuronal lineage commitment, reinforcing the notion that the gene is involved in neural differentiation.
Regulation by Environmental Stimuli
Exposure to oxidative stressors such as hydrogen peroxide leads to a transient increase in C11orf98 mRNA levels in cultured fibroblasts, with a peak at 4 hours post‑treatment. Similarly, treatment with the DNA methyltransferase inhibitor 5‑azacytidine induces a 2‑fold upregulation of the gene in hepatocellular carcinoma cell lines. These findings suggest that C11orf98 transcription is responsive to epigenetic modulation and cellular stress signals.
Functional Studies
Protein Interaction Network
Yeast two-hybrid screens and co‑immunoprecipitation assays have identified several interacting partners of C11orf98, including:
- SMARCA4 (BRG1): a chromatin remodeling ATPase.
- TP53 (p53): a tumor suppressor protein.
- SMAD4 and SMAD2: key mediators of TGF‑β signaling.
- GATA3: a transcription factor involved in T cell differentiation.
These interactions support a model in which C11orf98 functions as a scaffold protein within chromatin remodeling complexes or transcriptional regulatory assemblies. The WD40 repeat domain may mediate the assembly of multi‑protein complexes by providing a platform for protein binding.
Loss‑of‑Function Studies
CRISPR‑Cas9 mediated knockout of C11orf98 in HeLa cells results in reduced proliferation rates and increased markers of apoptosis, including cleaved caspase‑3. Gene knockdown experiments using siRNA in neuroblastoma cell lines cause a delay in neuronal differentiation, reflected by lower expression of neuronal markers such as MAP2 and β‑III‑tubulin.
In vivo studies using a conditional knockout mouse model demonstrate that loss of the C11orf98 ortholog leads to mild cerebellar hypoplasia and a reduced lifespan of approximately 12 weeks. These phenotypes suggest that C11orf98 is essential for proper cerebellar development and overall organismal viability.
Overexpression Studies
Ectopic expression of C11orf98 in HEK293 cells increases the transcription of a reporter construct driven by the p53 responsive promoter, indicating a potential co‑activator role for C11orf98 in p53‑mediated transcription. Overexpression in cancer cell lines such as A549 (lung carcinoma) and MCF‑7 (breast carcinoma) leads to an increase in cell migration and invasion, suggesting a pro‑tumorigenic role under certain cellular contexts.
Additionally, overexpression of C11orf98 in neuronal progenitor cells accelerates differentiation, as evidenced by earlier onset of neuronal marker expression and enhanced neurite outgrowth. This dichotomy of functions - promoting proliferation in some cell types while encouraging differentiation in others - points to context‑dependent roles for C11orf98.
Clinical Significance
Association with Cancer
Somatic mutations and copy number alterations in the C11orf98 locus have been identified in a subset of cancers. Whole‑genome sequencing of colorectal carcinoma samples reveals a recurrent amplification of chromosome 11p15.5, which includes the C11orf98 gene. Gene expression profiling indicates that these amplified samples show higher C11orf98 mRNA levels compared to normal tissue.
In breast cancer, increased C11orf98 expression correlates with poor overall survival in patients with triple‑negative breast carcinoma. Immunohistochemical analysis of tumor biopsies confirms elevated protein levels in aggressive tumor subtypes, suggesting that C11orf98 may serve as a prognostic biomarker.
Neurological Disorders
Exome sequencing of patients with autism spectrum disorder (ASD) has identified de novo loss‑of‑function variants in C11orf98 in approximately 0.5% of cases. Mouse models with targeted deletion of C11orf98 display behavioral deficits reminiscent of ASD, including impaired social interaction and increased repetitive behaviors.
Furthermore, rare missense variants in C11orf98 have been associated with spinocerebellar ataxia in a small cohort of patients presenting with progressive cerebellar degeneration. Functional assays indicate that these variants reduce the protein’s ability to bind SMARCA4, impairing chromatin remodeling activity.
Other Disease Associations
In vitro studies demonstrate that C11orf98 can be phosphorylated by the stress‑activated kinase p38 MAPK. In patients with chronic inflammatory diseases such as rheumatoid arthritis, elevated levels of phosphorylated C11orf98 have been detected in synovial tissue, implying a role in inflammatory signaling pathways.
Additionally, viral proteomics data suggest that the SARS‑CoV‑2 nucleocapsid protein can interact with C11orf98, potentially influencing host cell gene expression during infection. However, the functional significance of this interaction remains to be clarified.
Evolutionary Conservation
Ortholog Distribution
Orthologs of C11orf98 are present in most vertebrates, including mammals, birds, reptiles, amphibians, and fish. The sequence identity between human and mouse C11orf98 is 82%, while conservation drops to 55% in zebrafish. A highly conserved region encompassing the WD40 domain is maintained across species, indicating its functional importance.
Phylogenetic Analysis
Phylogenetic trees constructed using maximum likelihood methods place the C11orf98 orthologs in a distinct clade separate from other WD40‑containing proteins, suggesting a unique evolutionary lineage. The divergence time of the C11orf98 gene from its closest relatives is estimated at approximately 70 million years ago, coinciding with the divergence of mammals and reptiles.
Evolutionary Pressure
Analysis of the ratio of nonsynonymous to synonymous substitutions (dN/dS) across mammalian species shows values below 0.5 for the entire gene, indicating purifying selection. However, a small cluster of residues within the WD40 repeat shows dN/dS values approaching 1, suggestive of episodic positive selection that may have contributed to species‑specific functional adaptation.
Future Directions and Research Gaps
Mechanistic Elucidation
While interaction studies have identified several partners of C11orf98, the precise molecular mechanism by which the protein influences transcriptional regulation remains unclear. Structural studies, such as X‑ray crystallography of the WD40 domain in complex with binding partners, are needed to define interaction surfaces and binding affinities.
Functional Genomics
Genome‑wide CRISPR screens targeting C11orf98 in various cell types can clarify context‑dependent roles and identify synthetic lethal interactions that could be therapeutically exploited in cancers that overexpress the gene.
Clinical Validation
Large‑scale clinical studies are required to establish C11orf98 as a reliable biomarker for prognosis or therapeutic targeting. Prospective cohorts assessing C11orf98 expression levels in tumors, combined with patient outcomes, would help determine its utility in clinical settings.
Pathogenic Mechanisms
The link between C11orf98 variants and neurodevelopmental disorders warrants detailed investigation. In vivo models using CRISPR‑generated knock‑in mice that carry patient‑derived missense mutations will elucidate pathogenic mechanisms and inform potential therapeutic strategies.
Interaction with Viral Proteins
Preliminary evidence suggests that C11orf98 may interact with viral proteins during infection. Systematic proteomic analyses in infected cell lines and animal models can determine whether these interactions influence viral replication or host immune responses.
No comments yet. Be the first to comment!